Your goal determines protocol intensity and duration
CJC1295 promotes fat loss indirectly by elevating HGH, which boosts lipolysis and supports lean muscle preservation (human pharmacodynamic data)
Low exploratory: 1 nmol/kg subcutaneous (produces a measurable LH pulse within 30 minutes) Moderate support: 3 to 5 nmol/kg subcutaneous, daily or every other day, for 2 to 4 weeks Two forms exist: kisspeptin-54 (full-length, longer-acting, better studied in clinical trials) and kisspeptin-10 (C-terminal fragment, shorter-acting)
Shaking can cause the peptide to foam and may even denature or damage the delicate protein structure of the tirzepatide
GLP-1 agonists are not expensive to produce, however, and the patent on Ozempic expired in January of 2026 in Canada and China (and lasts until 2030 in the U.S.), but I expect the market to bring the costs down dramatically over the next few years